KNSA
NEUTRAL
$47.08
Live
Kiniksa Pharmaceuticals International, plc · NASDAQ
Target $57.38
(+21.9%)
$19.41
52W Range
$50.03
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$3.6B
P/E
62.77
ROE
11.7%
Profit margin
8.7%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
KNSA exhibits strong deterministic health with a Piotroski F-Score of 7/9 and a pristine balance sheet (Debt/Equity 0.02), yet it faces a severe valuation disconnect. The current price of $47.08 trades at a massive premium to its Graham Number ($11.20) and Intrinsic Value ($5.25), suggesting the market is pricing in aggressive future growth. While revenue growth is impressive at 65% YoY, the company has missed earnings estimates in 4 consecutive quarters with an average surprise of -35.29%. This fundamental instability, coupled with heavy C-suite insider selling and a bearish technical trend, offsets the strong financial health.
Key Strengths
Strong Piotroski F-Score (7/9) indicating robust financial health
Exceptional liquidity with a Current Ratio of 3.79 and Quick Ratio of 3.09
Negligible leverage with a Debt/Equity ratio of 0.02
High top-line momentum with 65% YoY revenue growth
Strong historical price performance (+152.4% over 1 year)
Key Risks
Extreme valuation premium relative to Graham and Intrinsic value baselines
Consistent failure to meet earnings expectations (0/4 beats in last 4 quarters)
Bearish insider sentiment with significant selling by CEO, CFO, and COO
Weak technical trend (10/100) suggesting a potential trend reversal
High P/E ratio (62.77) makes the stock highly sensitive to any growth deceleration
AI Fair Value Estimate
Based on comprehensive analysis
$28.5
-39.5% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
53
Moderate
20
65
85
95
0
AI Verdict
Speculative Growth
Key drivers: Pristine balance sheet, High revenue growth, Severe valuation gap, C-suite insider selling
Confidence
80%
Value
20/100
Ref P/E 62.77, Graham Number $11.2
Positives
- Forward P/E (29.03) is significantly lower than trailing P/E
Watchpoints
- Price is >4x the Graham Number
- Price is >8x the Intrinsic Value
- High P/B ratio of 6.33
Future
65/100
Ref Growth rates and Earnings surprises
Positives
- 65% YoY Revenue growth
- Strong analyst target price of $57.38
Watchpoints
- Consistent earnings misses
- Negative Q/Q EPS growth (-26.1%)
Past
85/100
Ref Historical price performance
Positives
- Massive 1Y return (+152.4%)
- Strong 3Y and 5Y growth trajectories
Watchpoints
- Recent 1-week decline (-3.6%)
Health
95/100
Ref Piotroski F-Score and Liquidity ratios
Positives
- Piotroski F-Score 7/9
- Very low Debt/Equity (0.02)
- High Current Ratio (3.79)
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Ref Yield N/A
Positives
No standout positives identified.
Watchpoints
- No dividend payments
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$47.08
Analyst Target
$57.38
Upside/Downside
+21.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KNSA and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International, plc
Primary
|
+191.5% | +337.6% | +152.4% | +24.2% | +1.7% | -3.6% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+604.6% | +370.5% | -15.4% | -6.0% | -6.9% | -1.6% |
|
ACAD
ACADIA Pharmaceuticals Inc.
Peer
|
-31.3% | +1.1% | +22.8% | -12.7% | -8.3% | -7.0% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
|
IRTC
iRhythm Holdings, Inc.
Peer
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
KNS
Kiniksa Pharmaceuticals International, plc
Primary
5Y
+191.5%
3Y
+337.6%
1Y
+152.4%
6M
+24.2%
1M
+1.7%
1W
-3.6%
ADM
ADMA Biologics, Inc.
Peer
5Y
+604.6%
3Y
+370.5%
1Y
-15.4%
6M
-6.0%
1M
-6.9%
1W
-1.6%
ACA
ACADIA Pharmaceuticals Inc.
Peer
5Y
-31.3%
3Y
+1.1%
1Y
+22.8%
6M
-12.7%
1M
-8.3%
1W
-7.0%
AMR
Amneal Pharmaceuticals, Inc.
Peer
5Y
+69.5%
3Y
+727.3%
1Y
+34.6%
6M
+18.3%
1M
-19.5%
1W
-10.7%
IRT
iRhythm Holdings, Inc.
Peer
5Y
+43.4%
3Y
-13.2%
1Y
+16.6%
6M
-34.6%
1M
-3.7%
1W
-1.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
62.77
Forward P/E
29.03
PEG Ratio
N/A
P/B Ratio
6.33
P/S Ratio
5.32
EV/Revenue
4.72
EV/EBITDA
40.61
Market Cap
$3.6B
Profitability
Profit margins and return metrics
Profit Margin
8.71%
Operating Margin
9.78%
Gross Margin
54.66%
ROE
11.73%
ROA
7.18%
Growth
Revenue and earnings growth rates
Revenue Growth
+65.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+64.95%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
3.79
Strong
Quick Ratio
3.09
Excellent
Cash/Share
$5.41
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
55.0%
Op. Margin
9.8%
Net Margin
7.0%
Total Assets
$0.8B
Liabilities
$0.2B
Equity
$0.6B
Debt/Equity
0.35x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.1B
FCF Yield
99%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-28
$N/A
2026-02-24
$0.17
-57.3% surprise
2025-10-28
$0.23
-37.3% surprise
2025-07-29
$0.23
-11.3% surprise
Healthcare Sector Comparison
Comparing KNSA against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
62.77
This Stock
vs
87.11
Sector Avg
-27.9%
(Discount)
Return on Equity (ROE)
11.73%
This Stock
vs
-49.88%
Sector Avg
-123.5%
(Below Avg)
Profit Margin
8.71%
This Stock
vs
-9.43%
Sector Avg
-192.3%
(Weaker)
Debt to Equity
0.02
This Stock
vs
3.74
Sector Avg
-99.6%
(Less Debt)
Revenue Growth
65.0%
This Stock
vs
80.78%
Sector Avg
-19.5%
(Slower)
Current Ratio
3.79
This Stock
vs
3.72
Sector Avg
+1.8%
(Better)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals...
|
NEUTRAL | $3.6B | 62.77 | 11.7% | 8.7% | $47.08 | |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.61B | 25.25 | 35.6% | 28.8% | $15.15 | Compare |
|
ACAD
ACADIA Pharmaceuticals Inc.
|
NEUTRAL | $3.51B | 8.96 | 39.9% | 36.5% | $20.61 | Compare |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | Compare |
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | Compare |
KNSA
Kiniksa...
NEUTRAL
Mkt Cap
$3.6B
P/E
62.8
ROE
11.7%
Price
$47.08
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-07 | MOAT ROSS | Chief Operating Officer | Stock Award | 2,477 | - |
| 2026-04-07 | TESSARI EBEN | Officer | Stock Award | 2,726 | - |
| 2026-04-07 | MEGNA MICHAEL R | Officer | Option Exercise | 3,932 | $3,932 |
| 2026-04-07 | PATEL SANJIV K | Chief Executive Officer | Option Exercise | 17,269 | $75,400 |
| 2026-04-07 | PAOLINI JOHN F | Officer | Stock Award | 2,497 | - |
| 2026-04-07 | RAGOSA MARK | Chief Financial Officer | Stock Award | 2,694 | - |
| 2026-04-06 | MOAT ROSS | Chief Operating Officer | Sale | 2,367 | $114,989 |
| 2026-04-06 | PATEL SANJIV K | Chief Executive Officer | Sale | 7,278 | $363,973 |
| 2026-04-06 | QUART BARRY D | Director | Sale | 6,901 | $345,050 |
| 2026-04-06 | QUART BARRY D | Director | Option Exercise | 6,901 | $98,891 |
| 2026-04-01 | MOAT ROSS | Chief Operating Officer | Stock Award | 5,808 | - |
| 2026-04-01 | TESSARI EBEN | Officer | Stock Award | 5,975 | - |
| 2026-04-01 | MEGNA MICHAEL R | Officer | Stock Award | 7,564 | - |
| 2026-04-01 | PATEL SANJIV K | Chief Executive Officer | Stock Award | 21,327 | - |
| 2026-04-01 | PAOLINI JOHN F | Officer | Stock Award | 5,831 | - |
MOAT ROSS
Chief Operating Officer
2026-04-07
2,477 shares
TESSARI EBEN
Officer
2026-04-07
2,726 shares
MEGNA MICHAEL R
Officer
2026-04-07
3,932 shares
·
$3,932
PATEL SANJIV K
Chief Executive Officer
2026-04-07
17,269 shares
·
$75,400
PAOLINI JOHN F
Officer
2026-04-07
2,497 shares
RAGOSA MARK
Chief Financial Officer
2026-04-07
2,694 shares
MOAT ROSS
Chief Operating Officer
2026-04-06
2,367 shares
·
$114,989
PATEL SANJIV K
Chief Executive Officer
2026-04-06
7,278 shares
·
$363,973
QUART BARRY D
Director
2026-04-06
6,901 shares
·
$345,050
QUART BARRY D
Director
2026-04-06
6,901 shares
·
$98,891
MOAT ROSS
Chief Operating Officer
2026-04-01
5,808 shares
TESSARI EBEN
Officer
2026-04-01
5,975 shares
MEGNA MICHAEL R
Officer
2026-04-01
7,564 shares
PATEL SANJIV K
Chief Executive Officer
2026-04-01
21,327 shares
PAOLINI JOHN F
Officer
2026-04-01
5,831 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
8 analysts
Wells Fargo
2026-02-25
Overweight
Overweight
Wedbush
2026-02-25
Outperform
Outperform
Canaccord Genuity
2026-02-19
Buy
Wedbush
2026-01-13
Outperform
Outperform
Goldman Sachs
2025-10-29
Buy
Buy
Citigroup
2025-10-17
Buy
Buy
Past News Coverage
Recent headlines mentioning KNSA from our newsroom.
Newest → oldest
No matching news yet.